134 related articles for article (PubMed ID: 30871861)
1. Essential structure of orexin 1 receptor antagonist YNT-707, part III: Role of the 14-hydroxy and the 3-methoxy groups in antagonistic activity toward the orexin 1 receptor in YNT-707 derivatives lacking the 4,5-epoxy ring.
Yamamoto N; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem; 2019 Apr; 27(8):1747-1758. PubMed ID: 30871861
[TBL] [Abstract][Full Text] [Related]
2. Essential structure of orexin 1 receptor antagonist YNT-707, Part I: Role of the 4,5-epoxy ring for binding with orexin 1 receptor.
Yamamoto N; Ohrui S; Okada T; Yata M; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4176-4179. PubMed ID: 28739044
[TBL] [Abstract][Full Text] [Related]
3. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290
[TBL] [Abstract][Full Text] [Related]
4. Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in d-nor-nalfurafine derivatives.
Katoh K; Kutsumura N; Yamamoto N; Nagumo Y; Saitoh T; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128550. PubMed ID: 35041942
[TBL] [Abstract][Full Text] [Related]
5. Essential structure of orexin 1 receptor antagonist YNT-707, Part II: Drastic effect of the 14-hydroxy group on the orexin 1 receptor antagonistic activity.
Ohrui S; Yamamoto N; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Watanabe Y; Hayakawa D; Gouda H; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2018 Feb; 28(4):774-777. PubMed ID: 29338909
[TBL] [Abstract][Full Text] [Related]
6. Essential structure of orexin 1 receptor antagonist YNT-707, part V: Structure-activity relationship study of the substituents on the 17-amino group.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Feb; 30(3):126893. PubMed ID: 31879208
[TBL] [Abstract][Full Text] [Related]
7. Discovery of attenuation effect of orexin 1 receptor to aversion of nalfurafine: Synthesis and evaluation of D-nor-nalfurafine derivatives and analyses of the three active conformations of nalfurafine.
Nagumo Y; Katoh K; Iio K; Saitoh T; Kutsumura N; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Ogawa Y; Baba T; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2020 Sep; 30(17):127360. PubMed ID: 32738987
[TBL] [Abstract][Full Text] [Related]
8. Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors.
Katoh K; Yamamoto N; Ishikawa Y; Irukayama-Tomobe Y; Tanimura R; Saitoh T; Nagumo Y; Kutsumura N; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128527. PubMed ID: 35007722
[TBL] [Abstract][Full Text] [Related]
9. Structure-based development of a subtype-selective orexin 1 receptor antagonist.
Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P
Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies.
Nagase H; Yamamoto N; Yata M; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ishikawa Y; Ogawa Y; Hirayama S; Kuroda D; Watanabe Y; Gouda H; Yanagisawa M
J Med Chem; 2017 Feb; 60(3):1018-1040. PubMed ID: 28051300
[TBL] [Abstract][Full Text] [Related]
11. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology.
Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ
Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110
[TBL] [Abstract][Full Text] [Related]
12. Crystal Structures of Human Orexin 2 Receptor Bound to the Subtype-Selective Antagonist EMPA.
Suno R; Kimura KT; Nakane T; Yamashita K; Wang J; Fujiwara T; Yamanaka Y; Im D; Horita S; Tsujimoto H; Tawaramoto MS; Hirokawa T; Nango E; Tono K; Kameshima T; Hatsui T; Joti Y; Yabashi M; Shimamoto K; Yamamoto M; Rosenbaum DM; Iwata S; Shimamura T; Kobayashi T
Structure; 2018 Jan; 26(1):7-19.e5. PubMed ID: 29225076
[TBL] [Abstract][Full Text] [Related]
13. Structure and ligand-binding mechanism of the human OX1 and OX2 orexin receptors.
Yin J; Babaoglu K; Brautigam CA; Clark L; Shao Z; Scheuermann TH; Harrell CM; Gotter AL; Roecker AJ; Winrow CJ; Renger JJ; Coleman PJ; Rosenbaum DM
Nat Struct Mol Biol; 2016 Apr; 23(4):293-9. PubMed ID: 26950369
[TBL] [Abstract][Full Text] [Related]
14. Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2.
Sifferlen T; Boller A; Chardonneau A; Cottreel E; Gatfield J; Treiber A; Roch C; Jenck F; Aissaoui H; Williams JT; Brotschi C; Heidmann B; Siegrist R; Boss C
Bioorg Med Chem Lett; 2015 May; 25(9):1884-91. PubMed ID: 25838147
[TBL] [Abstract][Full Text] [Related]
15. Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.
Perrey DA; German NA; Decker AM; Thorn D; Li JX; Gilmour BP; Thomas BF; Harris DL; Runyon SP; Zhang Y
ACS Chem Neurosci; 2015 Apr; 6(4):599-614. PubMed ID: 25643283
[TBL] [Abstract][Full Text] [Related]
16. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
17. Oxadiazole Derivatives as Dual Orexin Receptor Antagonists: Synthesis, Structure-Activity Relationships, and Sleep-Promoting Properties in Rats.
Brotschi C; Roch C; Gatfield J; Treiber A; Williams JT; Sifferlen T; Heidmann B; Jenck F; Bolli MH; Boss C
ChemMedChem; 2019 Jul; 14(13):1257-1270. PubMed ID: 31066976
[TBL] [Abstract][Full Text] [Related]
18. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
19. Substituted cyclopentanes, tetrahydrofurans and pyrrolidines as orexin-1-receptor antagonists for treatment of various CNS disorders (WO2015/055994; WO2015/124932; WO2015/124934).
Boss C; Roch C
Expert Opin Ther Pat; 2016; 26(3):409-15. PubMed ID: 26593218
[TBL] [Abstract][Full Text] [Related]
20. The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders.
Boss C; Gatfield J; Brotschi C; Heidmann B; Sifferlen T; von Raumer M; Schmidt G; Williams JT; Treiber A; Roch C
ChemMedChem; 2020 Dec; 15(23):2286-2305. PubMed ID: 32937014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
